We are live on ! Find out more
GILD icon

Gilead Sciences

1,522 hedge funds and large institutions have $72.7B invested in Gilead Sciences in 2018 Q2 according to their latest regulatory filings, with 76 funds opening new positions, 544 increasing their positions, 725 reducing their positions, and 107 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.04% more ownership

Funds ownership: 78.96%79% (+0.04%)

3% less funds holding

Funds holding: 1,5631,522 (-41)

6% less capital invested

Capital invested by funds: $77.5B → $72.7B (-$4.82B)

22% less funds holding in top 10

Funds holding in top 10: 6047 (-13)

25% less repeat investments, than reductions

Existing positions increased: 544 | Existing positions reduced: 725

29% less first-time investments, than exits

New positions opened: 76 | Existing positions closed: 107

31% less call options, than puts

Call options by funds: $1.25B | Put options by funds: $1.82B

Holders
1,522
Holders Change
-41
Holders Change %
-2.62%
% of All Funds
34.84%
Holding in Top 10
47
Holding in Top 10 Change
-13
Holding in Top 10 Change %
-21.67%
% of All Funds
1.08%
New
76
Increased
544
Reduced
725
Closed
107
Calls
$1.25B
Puts
$1.82B
Net Calls
-$567M
Net Calls Change
-$452M
Name Holding Trade Value Shares
Change
Change in
Stake
CA
201
Commerzbank Aktiengesellschaft
Germany
$30.2M +$3.09M +43,815 +11%
GIBU
202
Gulf International Bank (UK)
United Kingdom
$30M +$708K +10,026 +2%
PAM
203
Panagora Asset Management
Massachusetts
$30M -$6.64M -93,993 -18%
Lord, Abbett & Co
204
Lord, Abbett & Co
New Jersey
$30M +$4.97M +70,334 +20%
NC
205
Nicholas Company
Wisconsin
$29.8M -$7.39M -104,625 -20%
GAM
206
Gotham Asset Management
New York
$29.5M -$8.55M -121,051 -23%
Macquarie Group
207
Macquarie Group
Australia
$29.4M +$2.07M +29,375 +8%
OC
208
Oppenheimer & Co
New York
$29.3M -$42.5M -601,960 -59%
FIM
209
Foresters Investment Management
New York
$28.9M -$3.55M -50,300 -11%
SLAM
210
Swiss Life Asset Management
$28.9M -$21.1M -299,355 -42%
SEI Investments
211
SEI Investments
Pennsylvania
$28.9M +$7.43M +105,146 +35%
PIM
212
Provident Investment Management
Michigan
$28.7M +$1.11M +15,707 +4%
ClearBridge Investments
213
ClearBridge Investments
New York
$28.6M +$23.1M +326,552 +421%
HighTower Advisors
214
HighTower Advisors
Illinois
$28.3M -$391K -5,537 -1%
EP
215
Elkfork Partners
Oregon
$28.2M -$235K -3,332 -0.8%
BMO
216
Beck Mack & Oliver
New York
$28M +$856K +12,125 +3%
MCM
217
Masters Capital Management
Georgia
$27.2M +$13M +183,780 +92%
MIM
218
MetLife Investment Management
New Jersey
$27.1M -$809K -11,453 -3%
OI
219
Oakbrook Investments
Illinois
$27M -$259K -3,665 -1%
RG
220
Renaissance Group
Kentucky
$26.5M -$613K -8,674 -2%
RSCM
221
Rock Springs Capital Management
Maryland
$25.9M +$3.64M +51,600 +16%
O
222
OrbiMed
New York
$25.8M
FAF
223
Fjarde Ap-fonden
Sweden
$25.8M +$141K +1,992 +0.5%
WFMPM
224
Woodley Farra Manion Portfolio Management
Indiana
$25.8M +$408K +5,777 +2%
SFM
225
Sphera Funds Management
Israel
$25.1M +$25.1M +355,000 New

GILD Hedge Fund Activity: Q2 2018 in Review

1,522 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2018, worth a combined $72.7B — down 6.2% from $77.5B a quarter earlier.

Sellers outnumbered buyers: 107 funds closed out of GILD and 76 opened new positions — a net loss of 31 holders — while 725 trimmed existing stakes and 544 added.

The largest buyer was Capital Research Global Investors, adding an estimated $995M. The largest seller was Fidelity Investments, cutting an estimated $361M.

  • 1,522 institutional investors held Gilead Sciences (GILD) as of Q2 2018, down from 1,563 in Q1 2018.
  • Funds reported $72.7B of Gilead Sciences stock for Q2 2018, down 6.2% quarter-over-quarter.
  • 76 funds opened new Gilead Sciences positions in Q2 2018 and 107 closed out, a net change of -31 holders.
  • The largest Gilead Sciences buyer in Q2 2018 was Capital Research Global Investors, an estimated $995M added.
  • The largest Gilead Sciences seller in Q2 2018 was Fidelity Investments, an estimated $361M sold.

Based on aggregated 13F filings for Q2 2018.